Table 1.
Characteristics of patients in the included trials.
| Study name | Phase | Malignancy | Lines | Treatment (No.) | Age (y) median (range) | <65y (No.) | ≥65y (No.) | OS | PFS | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall HR (95% CI) | HR (95%CI) <65 y | HR [(95%CI)] ≥65 y | Overall HR (95% CI) | HR (95%CI) <65 y | HR [(95%CI)] ≥65 y | |||||||||
| West et al. (4) (2019) | IMpower 130 | III | NSCLC | 1 | ATE+ CBDCA +nTxl(451) CBDCA +nTxl(228) |
64 (18–86) 65 (38–85) |
341 | 338 | 0.79 (0.64–0.98) | 0·79 (0.58–1.08) | 0.78 (0.58–1.05) | 0.64 (0.54–0.77) | 0.64 (0.5–0.82) | 0.64 (0.5–0.82) |
| Hellmann et al. (5) (2019) | CheckMate 227b | III | NSCLC | 1 | NIV+IPI (396) CDDP/CBDCA+Pem (397) |
64 (26–84) 64 (27–85) |
406 | 387 | 0.79 (0.65–0.96) | 0.70 (0.55–0.89) | 0.91 (0.70–1.13)# | NR | NR | NR |
| Jotte et al. (8) (2018) | IMpower 131 | III | NSCLC | 1 | ATE+ CBDCA+nTxl(343) CBDCA+ nTxl(340) |
65 (23–83) 65 (38–86) |
326 | 357 | NR | NR | NR | 0.71 (0.60–0.85) | 0.77 (0.61–0.99) | 0.62 (0.49–0.79)# |
| Papadimitrakopoulou et al. (39, 40) (2018) | IMpower 132 | III | NSCLC | 1 | ATE+ CBDCA/CDDP+ Pem(292) CBDCA/CDDP+ Pem(286) |
NR NR |
320 | 258 | 0.81 (0.64–1.03) | 0.89 (0.62–1.21) | 0.71 (0.50–1.01) | 0.60 (0.49–0.72) | 0.63 (0.49–0.80) | 0.55 (0.42–0.73) |
| Gandhi et al., (9) (2018) | KEYNOTE 189 | III | NSCLC | 1 | PEM+ CDDP/CBDCA+Pem (410) placebo+ CDDP/CBDCA+Pem(206) |
65. (34–84) 63.5(34–84) |
312 | 304 | 0.49 (0.38–0.64) | 0.43 (0.31–0.61) | 0.64 (0.43–0.95) | 0.52 (0.43–0.64) | 0.43 (0.32–0.56) | 0.75 (0.55–1.02) |
| Paz-Ares et al. (38) (2018) | KEYNOTE 407 | III | NSCLC | 1 | PEM+ CBDCA+Txl/nTxl(278) CBDCA+Txl/nTxl(281) |
65 (29–87) 65 (36–88) |
254 | 305 | 0.64 (0.49–0.85) | 0.52 (0.34–0.80) | 0.74 (0.51–1.07) | 0.56 (0.45–0.70) | 0.50 (0.37–0.69) | 0.63 (0.47–0.84) |
| Hellmann et al. (41) (2018) | CheckMate 227a | III | NSCLC | 1 | NIV+IPI (139) CDDP/CBDCA+Pem (160) |
64 (41–87) 64 (29–80) |
156 | 143 | NR | NR | NR | 0.58 (0.41–0.81) | 0.51 (0.34–0.77) | 0.59 (0.39–0.89)# |
| Antonia et al. (10, 42) (2018) | PACIFIC | III | NSCLC | ≥2 | DUR+ chemoradiotherapy(476) Placebo+ chemoradiotherapy(237) |
64 (31–84) 64 (23–90) |
391 | 322 | 0.68 (0.47–1.00) | 0.62 (0.44–0.86) | 0.76 (0.55–1.06) | 0.51 (0.41–0.63) | 0.43 (0.32–0.57) | 0.74 (0.54–1.01) |
| Socinski et al. (7) (2018) | IMpower 150 | III | NSCLC | 1 | ATE+Bev+CBDCA+Txl (400) Bev+CBDCA+Txl (400) |
63 (31–89) 63 (31–90) |
441 | 359 | 0.78 (0.64–0.96) | 0.65 (0.51–0.82) | 0.60 (0.41–0.87)# | 0.62 (0.52–0.74) | NR | NR |
| Govindan et al. (11) (2017) | CA184-104 | III | NSCLC | 1 | IPI+ CBDCA+Txl(388) Placebo+ CBDCA+Txl(361) |
64 (28–84) 64 (28–85) |
380 | 369 | 0.91 (0.77–1.07) | 0.82 (0.64–1.04) | 1.01 (0.80–1.28)# | 0.87 (0.75–1.01) | NR | NR |
#
NR (not reported); estimated HR calculated by a random-effects model.
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; NSCLC, non-small lung cancer; ATE, atezolizumab;PEM, pembrolizumab; NIV, nivolumab; DUR, durvalumab; CBDCA, carboplatin; Pem, pemetrexed; IPI, ipilimumab; CDDP, cisplatin; Txl, paclitaxel; nTxl, nab-pacltitaxel; Bev, bevacizumab.